JP6275137B2 - 治療薬分与デバイスおよびその作製方法 - Google Patents

治療薬分与デバイスおよびその作製方法 Download PDF

Info

Publication number
JP6275137B2
JP6275137B2 JP2015526643A JP2015526643A JP6275137B2 JP 6275137 B2 JP6275137 B2 JP 6275137B2 JP 2015526643 A JP2015526643 A JP 2015526643A JP 2015526643 A JP2015526643 A JP 2015526643A JP 6275137 B2 JP6275137 B2 JP 6275137B2
Authority
JP
Japan
Prior art keywords
drug
eye
corneal
nanowafer
release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2015526643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524473A (ja
JP2015524473A5 (enExample
Inventor
ガナシャム アチャリヤ，
ガナシャム アチャリヤ，
スティーブン シー． フルーグフェルダー，
スティーブン シー． フルーグフェルダー，
パイバ， シンティア エス． デ
パイバ， シンティア エス． デ
ジェニファー エル． シンプソン，
ジェニファー エル． シンプソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Original Assignee
Baylor College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine filed Critical Baylor College of Medicine
Publication of JP2015524473A publication Critical patent/JP2015524473A/ja
Publication of JP2015524473A5 publication Critical patent/JP2015524473A5/ja
Application granted granted Critical
Publication of JP6275137B2 publication Critical patent/JP6275137B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/005—Templates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
    • A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
    • A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A61F2310/00383—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C33/00—Moulds or cores; Details thereof or accessories therefor
    • B29C33/38—Moulds or cores; Details thereof or accessories therefor characterised by the material or the manufacturing process
    • B29C33/3842—Manufacturing moulds, e.g. shaping the mould surface by machining
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C39/00—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor
    • B29C39/02—Shaping by casting, i.e. introducing the moulding material into a mould or between confining surfaces without significant moulding pressure; Apparatus therefor for making articles of definite length, i.e. discrete articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/712—Containers; Packaging elements or accessories, Packages

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2015526643A 2012-08-06 2013-08-06 治療薬分与デバイスおよびその作製方法 Expired - Fee Related JP6275137B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261679908P 2012-08-06 2012-08-06
US61/679,908 2012-08-06
US201361775891P 2013-03-11 2013-03-11
US61/775,891 2013-03-11
PCT/US2013/053805 WO2014025792A1 (en) 2012-08-06 2013-08-06 Therapeutics dispensing device and methods of making same

Publications (3)

Publication Number Publication Date
JP2015524473A JP2015524473A (ja) 2015-08-24
JP2015524473A5 JP2015524473A5 (enExample) 2016-08-18
JP6275137B2 true JP6275137B2 (ja) 2018-02-07

Family

ID=50068523

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015526643A Expired - Fee Related JP6275137B2 (ja) 2012-08-06 2013-08-06 治療薬分与デバイスおよびその作製方法

Country Status (6)

Country Link
US (2) US10251778B2 (enExample)
EP (1) EP2879761A4 (enExample)
JP (1) JP6275137B2 (enExample)
AU (1) AU2013299785B2 (enExample)
CA (1) CA2881010A1 (enExample)
WO (1) WO2014025792A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5505760B2 (ja) 2005-09-27 2014-05-28 ティッシュテク・インコーポレーテッド 羊膜調製物及び精製組成物及びその使用方法
EP2968113B8 (en) * 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN107430118A (zh) * 2013-06-27 2017-12-01 广东盛泽康华生物医药有限公司 对自身免疫状况的分类与管理的方法与仪器
US10613356B2 (en) * 2013-09-09 2020-04-07 The General Hospital Corporation Remotely controllable lens device
FR3016881B1 (fr) * 2014-01-29 2016-03-04 Biocodex Traitement des degenerescences et des lesions photo-induites de la retine
CN110236239B (zh) 2014-02-10 2022-03-29 菲利普莫里斯生产公司 具有流体可渗透加热器组件的气溶胶生成系统
KR20170040798A (ko) 2014-08-08 2017-04-13 포사이트 비젼4, 인크. 수용체 티로신 키나제 억제제의 안정한 가용성 제제 및 그의 제조 방법
US12667548B2 (en) 2014-11-07 2026-06-30 Nacuity Pharmaceuticals, Inc. Treatment of retinitis pigmentosa and retinitis pigmentosa associated with Usher Syndrome with N-acetylcysteine amide
US20160243288A1 (en) * 2015-02-23 2016-08-25 Tissuetech, Inc. Apparatuses and methods for treating ophthalmic diseases and disorders
US12551509B2 (en) 2015-11-18 2026-02-17 Lucina Patent Holdco, Llc Acellular regenerative products and methods of their manufacture
MX2019004562A (es) 2016-10-19 2019-08-05 Swimc Llc Polimeros acrilicos y composiciones que contienen tales polimeros.
CA3057569A1 (en) * 2017-03-29 2018-10-04 Azura Ophthalmics Ltd. Agents for increasing meibomian gland lipid secretion
US20200253867A1 (en) 2017-09-22 2020-08-13 University Of Florida Research Foundation Devices and methods for reducing cystine crystals in vivo
US20190135741A1 (en) 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
WO2020146362A1 (en) * 2019-01-09 2020-07-16 Verily Life Sciences Llc Eye mounted device for therapeutic agent release
WO2020146660A1 (en) 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
WO2020150226A1 (en) * 2019-01-15 2020-07-23 University Of Utah Research Foundation Drug-delivering nerve wrap
CA3143071A1 (en) 2019-07-26 2021-02-04 Proqr Therapeutics Ii B.V. Ophthalmic compositions comprising viscosifying polymers and nucleic acids
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
US20210378993A1 (en) * 2020-06-08 2021-12-09 Nacuity Pharmaceuticals, Inc. Treatment of cystinosis
EP3922282A1 (en) * 2020-06-09 2021-12-15 Dompe' Farmaceutici S.P.A. New drug delivery system for ophtalmic use
US12589072B2 (en) 2020-11-11 2026-03-31 Hadasit Medical Research Services And Development Ltd. Bioadhesive film and methods of use thereof
WO2022204374A1 (en) * 2021-03-24 2022-09-29 Ocular Therapeutix, Inc. Implant injector device
IT202200008621A1 (it) * 2022-04-29 2023-10-29 Sifi Spa Composizione farmaceutica in microemulsione per il trattamento dei disturbi del segmento anteriore dell'occhio

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788957A (en) * 1991-10-15 1998-08-04 Advanced Corneal Systems, Inc. Enzyme-orthokeratology
US7070590B1 (en) * 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
DE60025539T2 (de) * 1999-11-01 2006-07-27 Praful Poway Doshi Getönte kontaktlinse aus kunststoff und verfahren zu deren herstellung
DE60219607T2 (de) 2001-01-09 2007-12-27 Microchips, Inc., Bedford Flexible mikrochip-vorrichtungen zur ophthalmologischen und anderen applikation
WO2006039558A2 (en) 2004-10-09 2006-04-13 Formurex, Inc. Ocular agent delivery systems
US20070141106A1 (en) * 2005-10-19 2007-06-21 Bonutti Peter M Drug eluting implant
US7878650B2 (en) * 2006-06-29 2011-02-01 Fritsch Michael H Contact lens materials, designs, substances, and methods
AU2007338210B2 (en) * 2006-12-22 2013-01-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
US9125807B2 (en) * 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
WO2009042231A2 (en) * 2007-09-27 2009-04-02 Akina, Inc. Sol-gel phase-reversible hydrogel templates and uses thereof
EP2962682B1 (en) * 2008-12-11 2018-03-28 Massachusetts Institute Of Technology Method of making a contact lens drug delivery device
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
JP5890182B2 (ja) * 2009-02-12 2016-03-22 インセプト エルエルシー ヒドロゲルプラグによる薬物送達
EP2427179A4 (en) * 2009-05-04 2013-09-11 Psivida Inc POROUS PARTICLES FOR THE RELEASE OF SILICIUM MEDICINES
US9005649B2 (en) * 2009-07-14 2015-04-14 Board Of Regents, The University Of Texas System Methods for making controlled delivery devices having zero order kinetics
AU2011285637B2 (en) 2010-08-05 2014-10-30 Forsight Vision4, Inc. Subconjunctival implant for posterior segment drug delivery

Also Published As

Publication number Publication date
JP2015524473A (ja) 2015-08-24
US10251778B2 (en) 2019-04-09
CA2881010A1 (en) 2014-02-13
WO2014025792A1 (en) 2014-02-13
AU2013299785A1 (en) 2015-02-19
US20190282398A1 (en) 2019-09-19
US20150190279A1 (en) 2015-07-09
AU2013299785B2 (en) 2017-09-07
EP2879761A1 (en) 2015-06-10
EP2879761A4 (en) 2016-03-02

Similar Documents

Publication Publication Date Title
AU2013299785B2 (en) Therapeutics dispensing device and methods of making same
Lanier et al. Review of approaches for increasing ophthalmic bioavailability for eye drop formulations
Kwon et al. Potential therapeutic usage of nanomedicine for glaucoma treatment
Gan et al. Recent advances in topical ophthalmic drug delivery with lipid-based nanocarriers
Achouri et al. Recent advances in ocular drug delivery
Carvalho et al. Sustained drug release by contact lenses for glaucoma treatment—A review
EP3233056B1 (en) Sunitinib formulations and methods for use thereof in treatment of ocular disorders
Calles et al. Polymers in ophthalmology
Ratay et al. Modern therapeutic approaches for noninfectious ocular diseases involving inflammation
Sah et al. Medical management of glaucoma: focus on ophthalmologic drug delivery systems of timolol maleate
Wang et al. Injectable drug-loaded thermosensitive hydrogel delivery system for protecting retina ganglion cells in traumatic optic neuropathy
Sharma et al. A mini-review on new developments in nanocarriers and polymers for ophthalmic drug delivery strategies
Billowria et al. Topical advances in mucoadhesive ocular drug delivery system
HS Boddu Polymeric nanoparticles for ophthalmic drug delivery: an update on research and patenting activity
Das et al. Drug delivery to eye: Special reference to nanoparticles
Wang et al. Recent advances and future perspectives of long-acting ophthalmic preparations (LAOPs) in clinical applications
US20200206137A1 (en) Microparticle formulations for delivery of active agents
Nair et al. Current trends in ocular drug delivery systems and its applications
Khokhar Ocular drug Delivery system-a review based on ocuserts
Mostafa et al. Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases. Pharmaceutics 2023; 15: 1746
Zafar et al. Nanotechnology for transcorneal drug targeting in glaucoma: challenges and progress
Mustafa Ophthalmology: Navigating ocular barriers with advanced nanocarriers
Chang Recent advances in ophthalmic drug delivery
Bhaskar et al. Eye Drops to smart gels: The future of ocular drug delivery.
Chen et al. Medical Treatment Strategy for Glaucoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160629

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160629

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170413

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170728

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171018

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180109

R150 Certificate of patent or registration of utility model

Ref document number: 6275137

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees